You already took the first shot. The chat went quiet. You are trying to work out if this is normal, or if you are on your own.
People search this because the first week is often about adjusting, not the scale. Feeling nothing yet is common. Feeling awful is common too. Neither one means you should sit with a needle and no one who has read your chart.
Why people stop so early
Early drop-off is real.
Blue Health Intelligence looked at nearly 170,000 commercial plan members on these drugs for weight management. 30 percent of those patients stopped in the first month. 58 percent stopped before a benefit the study counted as clinically meaningful. People who saw a doctor more often were more likely to stay on.
A 2026 national survey in the Journal of Managed Care and Specialty Pharmacy asked 440 adults who had already stopped. 20.2 percent of those people said they stopped in the first month. Cost led the reasons at 36.1 percent. Side effects were next at 33.3 percent.
Nausea is the effect people mention first. The approved labeling for weekly semaglutide used for weight reduction lists nausea as common. Diarrhea shows up. Constipation does too. Some of it is mild. Some of it is not. Call your clinician if it is more than you can manage, or if you cannot keep fluids down.
Nausea is common in the first weeks. Eat smaller meals, drink water, and call your clinician if you cannot keep fluids down.
Who is supposed to pick up
A tracking number will not talk you through a bad Tuesday. Ask who answers after the first dose, and what they do if you feel awful.
Living+ charges one set monthly price. That covers the medication if a clinician prescribes it, provider care with unlimited provider visits, two one-on-one coaching sessions a month, and 24/7 care-team support. There is no separate visit fee. You can pause or cancel any time. If a clinician declines you, the charge is refunded.
If a clinician prescribes a compounded medication, it is not FDA-approved.
A coach is not a promise that you will feel well or that the scale will move. Talk to your provider about who actually answers.
Sources
- DiStefano MJ et al. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026;32(8):903-910. PMC13403254
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (telehealth red flags after medication arrives)
- FDA: Dosing errors associated with compounded injectable semaglutide products
- FDA: Compounding and the FDA questions and answers (compounded drugs are not FDA-approved)
- DailyMed: Wegovy (semaglutide) prescribing information, nausea listed among common adverse reactions
See what a Living+ plan costs and whether it fits.
